Cutaneous hyperpigmentation following venous sclerotherapy treated with deferoxamine mesylate

被引:3
|
作者
Lopez, L
Dilley, RB
Henriquez, JA
机构
[1] Unidad Enfermedades Circulatorias, Vasc Lab, Tijuana, BC, Mexico
[2] Scripps Clin, Div Cardiothorac & Vasc Surg, La Jolla, CA USA
关键词
D O I
10.1046/j.1524-4725.2001.01052.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background. Cutaneous hyperpigmentation after venous sclerotherapy is an adverse sequelae of difficult management. Objective. To evaluate the degree of depigmentation with the use of deferoxamine mesylate (DM) in patients with postsclerotherapy hyperpigmentation treated with polydocanol (POL) for telangiectasias and reticular veins (0.2-5 mm diameter) and varicose veins (5-8 mm diameter). Methods. The experimental group of 36 female patients (mean age 37 years) was divided in two groups. Group I consisted of 30 patients who were treated with POL at 0.25-0.50% concentration for telangiectasias and reticular veins. Group II consisted of six patients with prolonged postsclerotherapy hyperpigmentation (more than 6 months after treatment) in varicose veins that had been treated with POL at 1.5 % concentration each week. Groups I and II were injected with DM 500 mg subcutaneously once a week until 81-100% depigmentation was reached. In group I, DM was injected at the time of sclerotherapy. These groups were compared to their respective control groups with similar conditions but allowing spontaneous depigmentation without DM. Evaluation was undertaken clinically and photographically, and the number of days required to reach the desired depigmentation of 81-100% was determined. Results. When DM was used, depigmentation of 81-100% was observed in group I at 27 days, and for group II in 46 days. In each control group, similar depigmentation was seen at 150 +/- 19 and 255 +/- 11 days, respectively. Comparing results, there was a reduction in the time to depigmentation of 82% for each group (P<.0001). Conclusion. The weekly subcutaneous administration of DM 500 mg reduces the time to depigmentation by 82% in patients with postsclerotherapy cutaneous hyperpigmentation treated for telangiectasias and reticular veins and prolonged postsclerotherapy hyperpigmentation in varicose veins. In this study we could not explain why such variability exists in the length of time to spontaneous depigmentation.
引用
收藏
页码:795 / 798
页数:4
相关论文
共 50 条
  • [1] Cutaneous hyperpigmentation following bleomycin sclerotherapy for vascular malformations
    Davis, Kyle P.
    Gaffey, Megan M.
    Kompelli, Anvesh R.
    Richter, Gresham T.
    PEDIATRIC DERMATOLOGY, 2022, 39 (01) : 103 - 106
  • [2] CUTANEOUS NECROSIS, TELANGIECTATIC MATTING, AND HYPERPIGMENTATION FOLLOWING SCLEROTHERAPY - ETIOLOGY, PREVENTION, AND TREATMENT
    GOLDMAN, MP
    SADICK, NS
    WEISS, RA
    DERMATOLOGIC SURGERY, 1995, 21 (01) : 19 - 29
  • [3] Pycnogenol ® prevents skin hyperpigmentation following sclerotherapy
    Cesarone, Maria R.
    Belcaro, Gianni
    Cox, David
    Scipione, Valeria
    Scipione, Claudia
    Dugall, Mark
    Cornelli, Umberto
    Hosoi, Morio
    Feragalli, Beatrice
    Hu, Shu
    Cotellese, Roberto
    MINERVA SURGERY, 2024, 79 (02): : 161 - 165
  • [4] Cutaneous hyperpigmentation following nonpermanent henna tattoo
    Bukhari, IA
    SAUDI MEDICAL JOURNAL, 2005, 26 (01) : 142 - 144
  • [5] Cutaneous hyperpigmentation following nonpermanent henna tattoo
    Shelleh, HH
    SAUDI MEDICAL JOURNAL, 2005, 26 (08) : 1315 - 1315
  • [6] Cutaneous hyperpigmentation in a patient treated with minocycline for rheumatoid arthritis
    Prouteau, C.
    Guennoc, X.
    Tisseau, L.
    Darrieux, L.
    Safa, G.
    ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE, 2018, 145 (02): : 152 - 154
  • [7] SELECTIVE CUTANEOUS HYPERPIGMENTATION IN MICE FOLLOWING ZIDOVUDINE ADMINISTRATION
    OBUCH, ML
    BAKER, G
    ROTH, RI
    YEN, TSB
    LEVIN, J
    BERGER, TG
    ARCHIVES OF DERMATOLOGY, 1992, 128 (04) : 508 - 513
  • [8] Cutaneous hyperpigmentation following nonpermanent henna tattoo - Response
    Bukhari, IA
    SAUDI MEDICAL JOURNAL, 2005, 26 (08) : 1316 - 1316
  • [9] Cutaneous reactions to imatinib mesylate treated by topical steroid
    Ujiie, H
    Shimizu, T
    Shimizu, H
    AMERICAN JOURNAL OF HEMATOLOGY, 2005, 78 (03) : 246 - 246
  • [10] A PREDICTOR FOR SIDE-EFFECTS IN PATIENTS WITH ALZHEIMERS-DISEASE TREATED WITH DEFEROXAMINE MESYLATE
    KRUCK, TPA
    FISHER, EA
    MCLACHLAN, DRC
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1993, 53 (01) : 30 - 37